JPRN-UMIN000006021已完成2 期
Trimodality therapy in EGFR mutation status negative patients with stage IV non-small cell lung cancer - Trimodality therapy in EGFR mutation status negative patients with stage IV non-small cell lung cancer
Iseikai Hospital0 个研究点目标入组 45 人开始时间: 2011年7月31日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active co-morbidities. 2)Symptomatic brain metastasis. 3)Interstitial lung disease. 4)Active infection. 5)Severe heart disease. 6)Massive pleural, cardiac effusion, or ascites needed with treatment. 7)Neurological disorder. 8)Active double cancer. 9)Psychotic disorder. 10)Histology of grave allergic reaction. 11)Pregnancy, breast feeding and supected pregnancy. 12)Patients whose participation in the trial is judged to be inappropriate.
研究者
相似试验
招募中
2 期
ntreated IIIB/IV period with the EGFR mutation in the gene, phase II study of Gefitinib and the pemetrexed / bevacizumab combination maintenance therapy after Gefitinib and the cisplatin / pemetrexed / bevacizumab combination induction therapy for non-squamous epithelium non-small cell lung cancer of the latter recurrenceJPRN-UMIN000016550International University of Health and Welfare Respiratory Disease Center27
已完成
不适用
2nd-line Tarceva+ALIMTA for EGFR mutation negative non-small, non-squamous lung cancer (TALIMTA STUDY)non-sq NSCLCJPRN-UMIN000002453Respiratory Medicine, Kyoto University Hospital30
已完成
不适用
a Study of EGFR & ALK Test in Lung cancer patients.CTRI/2017/10/010086Tata Memorial Hospital500
招募中
不适用
Clinical and Epidemiological Study of EGFR Mutation and EML4-ALK Fusion Gene Among Indian Patients with Adenocarcinoma LungCTRI/2012/04/002589Pfizer India500
招募中
不适用
The continuous evaluation of EGFR mutation in EGFR-mutation positive lung cancer patients during EGFR TKI treatmentnon-small cell lung cancerJPRN-UMIN000037232Advanced Cancer Translational Research Institute100